Recent data suggest beneficial effects of a dual PPAR-α/γ agonist (Saroglitazar) on NAFLD/NASH in two phase II trials with respectively 106 and 16 subjects, and a phase IIb trial with a PPAR pan agonist (Lanifibranor) in 247 subjects [14–16]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.